ArticleAntimicrobial agents and chemotherapy2002
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis.PloS one · 2015Pooled it
- Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.Antimicrobial agents and chemotherapy · 2013Trial
- Trial
- Early preclinical development ofiScience · 2025Article
- Rapid Microarray-Based Detection of Rifampin, Isoniazid, and Fluoroquinolone Resistance in Mycobacterium tuberculosis by Use of a Single Cartridge.Journal of clinical microbiology · 2018Article
- Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis.Frontiers in molecular biosciences · 2017Review
- Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.The European respiratory journal · 2014Article
- Investigational antimicrobial agents of 2013.Clinical microbiology reviews · 2013Review
- Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.Future microbiology · 2012Review
- Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective.Ophthalmology and eye diseases · 2012Article
- Drugs in development for tuberculosis.Drugs · 2010Review
- In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.Antimicrobial agents and chemotherapy · 2010Article
- Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.Antimicrobial agents and chemotherapy · 2009Article
- New anti-tuberculosis agents amongst known drugs.Tuberculosis (Edinburgh, Scotland) · 2009Article
- New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Antimicrobial agents and chemotherapy · 2009Review
- Tuberculosis pharmacotherapy: strategies to optimize patient care.Expert opinion on pharmacotherapy · 2009Review
- Confronting the scientific obstacles to global control of tuberculosis.The Journal of clinical investigation · 2008Review
- In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.Antimicrobial agents and chemotherapy · 2007Article
- Treatment Options for HIV-Associated Tuberculosis.The Journal of infectious diseases · 2007Review
- Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.Antimicrobial agents and chemotherapy · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Gatifloxacin (GAT) and moxifloxacin (MXF) were evaluated in vitro to determine their activities against Mycobacterium tuberculosis. GAT was subsequently compared in a dose range study to isoniazid (INH) in a murine tuberculosis model. GAT was somewhat less active than INH. GAT and MXF were evaluated in mice infected with M. tuberculosis and were found to have similar activities. GAT was studied alone and in combination with ethambutol, ethionamide (ETA), and pyrazinamide (PZA) and compared to INH and rifampin (RIF). GAT appears to have sufficient activity alone and in combination with ETA with or without PZA to merit evaluation for treatment of tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.